MA47541A - Procédé permettant de produire des progéniteurs de lymphocytes t - Google Patents

Procédé permettant de produire des progéniteurs de lymphocytes t

Info

Publication number
MA47541A
MA47541A MA047541A MA47541A MA47541A MA 47541 A MA47541 A MA 47541A MA 047541 A MA047541 A MA 047541A MA 47541 A MA47541 A MA 47541A MA 47541 A MA47541 A MA 47541A
Authority
MA
Morocco
Prior art keywords
producing
lymphocyte progenitors
progenitors
lymphocyte
Prior art date
Application number
MA047541A
Other languages
English (en)
Inventor
Isabelle Andre
Marina Cavazzana
Kuiying Ma
John Tchen
Original Assignee
Hopitaux Paris Assist Publique
Fondation Imagine Inst Des Maladies Genetiques
Inst Nat Sante Rech Med
Univ Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hopitaux Paris Assist Publique, Fondation Imagine Inst Des Maladies Genetiques, Inst Nat Sante Rech Med, Univ Paris Descartes filed Critical Hopitaux Paris Assist Publique
Publication of MA47541A publication Critical patent/MA47541A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
MA047541A 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t MA47541A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13

Publications (1)

Publication Number Publication Date
MA47541A true MA47541A (fr) 2019-12-18

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047541A MA47541A (fr) 2017-02-13 2018-02-12 Procédé permettant de produire des progéniteurs de lymphocytes t

Country Status (17)

Country Link
US (5) US20200046767A1 (fr)
EP (2) EP4067482A1 (fr)
JP (2) JP7164798B2 (fr)
KR (1) KR102666158B1 (fr)
CN (1) CN110506110B (fr)
AU (1) AU2018217404B2 (fr)
BR (1) BR112019016672A8 (fr)
CA (1) CA3053294A1 (fr)
DK (1) DK3580330T3 (fr)
ES (1) ES2931530T3 (fr)
HU (1) HUE060548T2 (fr)
IL (1) IL268641B2 (fr)
MA (1) MA47541A (fr)
PL (1) PL3580330T3 (fr)
PT (1) PT3580330T (fr)
WO (1) WO2018146297A1 (fr)
ZA (1) ZA201905470B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4067482A1 (fr) * 2017-02-13 2022-10-05 Assistance Publique - Hôpitaux de Paris Procédé de génération de progéniteurs de lymphocytes t
US20200308540A1 (en) * 2017-09-29 2020-10-01 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
WO2019157597A1 (fr) 2018-02-14 2019-08-22 Sunnybrook Research Institute Procédé de génération de cellules de la lignée des lymphocytes t
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
AU2020265737A1 (en) * 2019-05-01 2021-12-02 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
KR20220042353A (ko) * 2019-06-24 2022-04-05 칠드런＇스 하스피틀 로스 앤젤레스 사람 흉선 세포 생성 및 t 세포 기능을 증진시키기 위한 bcl11b 과발현
US20220403326A1 (en) * 2019-11-14 2022-12-22 Peter William ZANDSTRA Media formulations and methods for producing progenitor t cells
JPWO2021200901A1 (fr) * 2020-03-31 2021-10-07
AU2021385606B2 (en) 2020-11-30 2026-02-05 Cho Pharma, Inc. Antibody for enrichment of cells
AU2022228364A1 (en) * 2021-03-05 2023-09-14 Factor Bioscience Inc. Engineered immune cell therapies
WO2022248354A1 (fr) * 2021-05-25 2022-12-01 Universiteit Gent Génération de précurseurs de lymphocytes t par agonisation du récepteur 2 du facteur de nécrose tumorale
EP4426319A1 (fr) 2021-11-04 2024-09-11 APHP (Assistance Publique - Hôpitaux de Paris) Méthode de génération de cellules nk
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
JP2026504155A (ja) 2023-01-27 2026-02-03 ノッチ セラピューティクス（カナダ）インコーポレイテッド 幹細胞／前駆細胞からｔ細胞系統集団を生成するための方法
EP4669327A1 (fr) * 2023-02-22 2025-12-31 Meiragtx Cell Therapies Procédé de régénération du thymus
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (fr) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Procédé de production de progéniteurs de lymphocytes t à partir de cellules souches pluripotentes humaines
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
JP2001525176A (ja) 1997-12-04 2001-12-11 デューク・ユニバーシティー Ｃｄ７＋ｃｄ３４−ｌｉｎ−造血細胞を単離し、使用する方法
WO2009097140A1 (fr) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Procédés d'immunothérapie tumorale prête à l'emploi utilisant des précurseurs de lymphocytes t allogéniques
WO2010031006A1 (fr) 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Thérapie cellulaire de tissus ischémiques
WO2010051634A1 (fr) 2008-11-07 2010-05-14 Sunnybrook Health Sciences Centre Lymphocytes t progéniteurs humains
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
US20130095079A1 (en) 2010-04-09 2013-04-18 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
WO2013074916A1 (fr) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Lymphocytes t car+ génétiquement modifiés pour éliminer l'expression du récepteur des lymphocytes t et/ou le système hla
EP2788476B1 (fr) * 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions et procédés pour la génération améliorée de cellules souches/progénitrices hématopoïétiques
US20150352180A1 (en) 2013-01-11 2015-12-10 The Trustee Of The University Of Pennsylvania Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation
CA2954168C (fr) 2013-08-02 2023-09-19 The Regents Of The University Of California Modification d'une immunite antivirale mediee par les cellules t par des cellules souches et des recepteurs d'antigene chimeriques
WO2015099134A1 (fr) 2013-12-26 2015-07-02 アストリム株式会社 Immunothérapie utilisant des cellules t précurseurs dérivées de cellules souches pluripotentes portant un gène du récepteur t réarrangé
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
WO2015162211A1 (fr) * 2014-04-24 2015-10-29 Miltenyi Biotec Gmbh Procédé de production automatisée de cellules t génétiquement modifiées
US10543257B2 (en) 2014-09-11 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
CA2989858A1 (fr) * 2015-06-17 2016-12-22 The Uab Research Foundation Complexe crispr/cas9 pour introduire un polypeptide fonctionnel dans des cellules de lignee cellulaire sanguine
US12076342B2 (en) 2016-04-08 2024-09-03 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
EP4067482A1 (fr) * 2017-02-13 2022-10-05 Assistance Publique - Hôpitaux de Paris Procédé de génération de progéniteurs de lymphocytes t

Also Published As

Publication number Publication date
ES2931530T3 (es) 2022-12-30
US20230293586A1 (en) 2023-09-21
BR112019016672A8 (pt) 2022-11-22
HUE060548T2 (hu) 2023-03-28
US20200046767A1 (en) 2020-02-13
JP7164798B2 (ja) 2022-11-02
BR112019016672A2 (pt) 2020-04-14
IL268641B2 (en) 2024-10-01
AU2018217404A2 (en) 2019-09-19
IL268641B1 (en) 2024-06-01
DK3580330T3 (da) 2022-12-05
JP2020513844A (ja) 2020-05-21
US11426430B2 (en) 2022-08-30
EP3580330B1 (fr) 2022-08-31
PT3580330T (pt) 2022-12-06
PL3580330T3 (pl) 2023-01-16
WO2018146297A1 (fr) 2018-08-16
US20210169935A1 (en) 2021-06-10
EP4067482A1 (fr) 2022-10-05
AU2018217404B2 (en) 2024-03-28
RU2019125600A3 (fr) 2021-11-03
EP3580330A1 (fr) 2019-12-18
RU2019125600A (ru) 2021-03-15
IL268641A (en) 2019-10-31
CN110506110A (zh) 2019-11-26
ZA201905470B (en) 2024-12-18
KR20190117550A (ko) 2019-10-16
AU2018217404A1 (en) 2019-09-05
US11638723B2 (en) 2023-05-02
US11642376B2 (en) 2023-05-09
JP2022185024A (ja) 2022-12-13
US20200390817A1 (en) 2020-12-17
KR102666158B1 (ko) 2024-05-16
US20210169934A1 (en) 2021-06-10
CA3053294A1 (fr) 2018-08-16
CN110506110B (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
ZA201901870B (en) Process for producing nonwoven
EP3392266A4 (fr) Procédé de synthèse de linaclotide
EP3718462A4 (fr) Procédé de détection
EP3302441A4 (fr) Procédés de production du brivaracetam
EP3322659A4 (fr) Procédé et système permettant de former des emballages
SG11201703273SA (en) Process for producing light olefins
EP3398957A4 (fr) Procédé de synthèse de l'ételcalcétide
SG11201607803QA (en) A draw solute for a forward osmosis process
EP3438272A4 (fr) Procédé de production de xylo-oligosaccharide
EP3296282A4 (fr) Procédé de production d'hydrohalofluorooléfines
EP3822259A4 (fr) Procédé de synthèse de valsartan
PL3364800T3 (pl) Sposób wytwarzania zasadniczo cylindrycznych artykułów
EP3764172A4 (fr) Procédé de servocommande
EP3513888A4 (fr) Procédé de coulée continue
EP3458948A4 (fr) Procédé de fourniture de notifications
EP3436571C0 (fr) Procédé de culture de lymphocyte b
SG11201703275TA (en) A process for producing light olefins
EP3424894A4 (fr) Procédé de production de butadiène
EP3564245A4 (fr) Dérivé de naphthobischalcogénadiazole et son procédé de production
EP3444253A4 (fr) Procédé de préparation de ad-35
EP3455210A4 (fr) Procédé de préparation de boscalide
LT3441765T (lt) Bazofilų aktyvacijos nustatymo būdas
GB201501500D0 (en) Apparatus & process
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives
GB2573695B (en) Method for detecting mitochondrial tRNA modification